Abstract
BackgroundIn vitro, the key B-cell cytokine BAFF (B-lymphocyte activating factor) differentially promotes the survival of transitional B-cells and plasmablasts through interaction with specific receptors. Following rituximab (RTX) therapy in patients...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
